ArticleBiomarker research2026

First-in-human phase Ia study of the covalent TEAD palmitoylation inhibitor BPI-460372 in patients with advanced solid tumors: pharmacokinetics, exposure-limited dosing, and early antitumor activity.

Hongge Liang et al.PubMed ↗Publisher ↗

No numbers read from the abstract.